Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | September 18, 2026 | September 21, 2026 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date September 18, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,840 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 6,801 · Balance 51,840 F1: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.
Olema Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18 | Direct | 29,500 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 21:30 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 6,801 | $1.93 | $13,125.93 |
DisclosureSEC source: 0002018686-26-000014 · form4-09212026_090921.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,840 F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 20:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0002018686-26-000012 · form4-06292026_080611.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 19, 2026 Filed Jun 22, 2026 20:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 7,907 | $1.66 | $13,125.62 |
DisclosureSEC source: 0002018686-26-000008 · form4-06222026_080600.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,039 F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0002018686-26-000010 · form4-06232026_090648.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 23:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 24,150 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0002018686-26-000006 · form4-04292026_110437.xml · derivative · entry 2 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2036-04-27 F2 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from April 28, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 23:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 2,911 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0002018686-26-000006 · form4-04292026_110437.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,911 Underlying: Common Stock · 2,911 shares Expires 2036-04-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on June 11, 2026, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 6,105 | $2.15 | $13,125.75 |
DisclosureSEC source: 0002018686-26-000002 · form4-03202026_090300.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,132 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 21:33 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 4,665 | $2.76 | $12,875.40 |
DisclosureSEC source: 0002018686-25-000007 · form4-12152025_091210.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,027 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 21:45 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 3,843 | $3.35 | $12,874.05 |
DisclosureSEC source: 0002018686-25-000004 · form4-09222025_090933.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,362 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 5,526 | $2.33 | $12,875.58 |
DisclosureSEC source: 0001415889-25-017821 · form4-06202025_080647.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,519 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 22:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001415889-25-017056 · form4-06122025_100652.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 21, 2025 Filed Mar 21, 2025 20:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 6,848 | $1.88 | $12,874.24 |
DisclosureSEC source: 0001415889-25-008771 · form4-03212025_080359.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,993 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:34 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 5,150 | $2.50 | $12,875.00 |
DisclosureSEC source: 0001415889-24-029482 · form4-12162024_091237.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,145 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 20:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 2,694 | $4.78 | $12,877.32 |
DisclosureSEC source: 0001415889-24-023755 · form4-09202024_080904.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,995 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 20:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 2,301 | $4.98 | $11,458.98 |
DisclosureSEC source: 0001415889-24-017843 · form4-06212024_080605.xml · nonDerivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,301 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 21:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001415889-24-015823 · form4-06062024_090628.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 21:28 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 61,100 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001415889-24-010769 · form4-04122024_090430.xml · derivative · entry 1 Raman Prakash · CIK 0002018686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,100 Underlying: Common Stock · 61,100 shares Expires 2034-04-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on May 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.